• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    IDEXX Laboratories Announces First Quarter Results

    5/1/25 6:30:00 AM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $IDXX alert in real time by email
    • Achieves first quarter revenue growth of 4% as reported and 5% organic, supported by CAG Diagnostics recurring revenue growth of 3% as reported and 4.5% organic.
    • Organic revenue growth supported by benefits from IDEXX execution drivers, including continued solid new business gains and strong year-over-year global premium instrument installed base growth, including over 300 IDEXX inVue Dx™ placements.
    • Delivers EPS of $2.96, an increase of 5% as reported and 7% on a comparable basis, supported by gross margin expansion of 90 basis points as reported and 80 basis points on a comparable basis.
    • Adjusts 2025 revenue guidance to $4,095 million - $4,210 million, an increase of $40 million or ~1% at midpoint, reflecting benefits of foreign exchange impacts updated from prior estimates.
    • Updates guidance for 2025 reported revenue growth to 5% - 8% and reported CAG Diagnostics recurring revenue growth to 4% - 7%, while maintaining consistent outlook for 6% - 9% organic revenue growth and CAG Diagnostics recurring revenue organic growth of 5% - 8%.
    • Updates 2025 EPS outlook to $11.93 - $12.43, reflecting $0.19 increase to EPS compared to prior guidance, supported by benefits from updated foreign exchange impacts and favorable adjustment to a now-concluded litigation matter expense accrual.

    IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, today announced first quarter results.

    "IDEXX drove solid execution in the first quarter while advancing key enablers of our innovation-driven growth strategy. At the end of March, IDEXX launched a first-of-its-kind innovation, IDEXX Cancer Dx™, in our North American reference laboratories," said Jay Mazelsky, President and Chief Executive Officer. "Customers have been asking for a way to diagnose cancer earlier because cancer is a leading cause of mortality in dogs and earlier detection provides better treatment options. This diagnostic panel for early detection of canine lymphoma brings exceptional levels of performance, turnaround time, and it is priced to allow veterinarian partners to include it in commonly used screening and sick patient testing panels."

    First Quarter Results

    The Company reports revenues of $998 million for the first quarter of 2025, an increase of 4% as reported and 5% organic, driven by Companion Animal Group ("CAG") growth of 3% as reported and 4% organic, and Water revenue growth of 5% as reported and 7% organic. CAG Diagnostics recurring revenue growth of 3% as reported and 4.5% organic was supported by double-digit IDEXX VetLab consumables organic revenue growth and benefits from IDEXX execution drivers, including 9% growth in IDEXX's global premium instrument installed base. IDEXX veterinary software, services and diagnostic imaging systems revenue increased 9% as reported and 7% organic.

    First quarter earnings per diluted share ("EPS") were $2.96, an increase of 5% as reported and 7% on a comparable basis, excluding a $0.08 per share benefit from a discrete litigation expense accrual adjustment.

    First Quarter Performance Highlights

    Companion Animal Group

    The Companion Animal Group generated revenue growth of 3% as reported and 4% organic for the quarter. Solid growth was supported by CAG Diagnostics recurring revenue growth of 3% as reported and 4.5% organic. CAG Diagnostics recurring revenue growth was supported by 5% reported and 8.5% organic gains in International regions. U.S. CAG Diagnostics recurring revenue growth of 3% as reported and organic continued to outpace sector growth levels in the first quarter.

    Additional U.S. companion animal practice key metrics are available in the Q1 2025 Earnings Snapshot accessible on the IDEXX website, www.idexx.com/investors.

    Sustained high levels of customer retention, net price gains, and benefits from net new customers, and an increase in diagnostic utilization supported expansion of CAG Diagnostics recurring revenues.

    • IDEXX VetLab® consumables generated 9% reported and 10% organic revenue growth supported by strong installed base growth across premium instrument platforms.
    • Reference laboratory diagnostic and consulting services generated flat reported and 1% organic revenue growth, including benefits from net price gains and modest volume gains in U.S. and International regions after adjusting for year-over-year equivalent days growth impact.
    • Rapid assay products revenues declined 3% as reported and declined 2% organic, with volumes impacted from the recent launch of the Catalyst® Pancreatic Lipase Test, which shifted some testing across modalities, offsetting net price benefits.

    Veterinary software, services and diagnostic imaging systems revenues grew 9% as reported and 7% organic, reflecting 10% as reported and 9% organic recurring revenue growth led by continued momentum in cloud-based software placements.

    Water

    Water revenues grew 5% as reported and 7% organic for the quarter, reflecting solid organic growth across regions.

    Livestock, Poultry and Dairy ("LPD")

    LPD revenues increased 1% as reported and 4% organic for the quarter, led by revenue gains in U.S. and Latin America.

    Gross Profit and Operating Profit

    Gross profits increased 5% as reported and 6% on a comparable basis. Gross margin of 62.4% increased 90 basis points as reported and 80 basis points on a comparable basis, supported by benefits from strong growth in IDEXX VetLab consumables revenue, improved instrument placement mix, and overall business mix.

    Operating margin was 31.7% for the quarter, higher than the prior year by 70 basis points as reported but lower by 10 basis points on a comparable basis, net of ~90 basis points benefit from the adjustment to the discrete litigation expense accrual. Operating margin results reflect 4% operating expense growth as reported and 8% on a comparable basis, net of 3% favorable impact from the adjustment to the discrete litigation expense accrual. Comparable operating expense growth was driven by higher R&D spend related to advancing the Company's growth and innovation agenda and higher sales and marketing expense aligned with commercial activities in support of new product launches and sector development.

    2025 Growth and Financial Performance Outlook

    The Company is updating its full year revenue growth guidance range to $4,095 million - $4,210 million, or reported growth of 5% - 8%, an increase of $40 million at midpoint. This reflects a positive adjustment of ~1% at midpoint to full year estimates for reported revenue growth, reflecting recent weakening of the U.S. dollar aligned with the foreign currency exchange rate assumptions set forth in this release. The Company is maintaining a consistent outlook for organic revenue growth projected at 6% - 9%.

    The Company updated its full year reported operating margin outlook of 31.1% - 31.6%, including ~180 basis points of impact from the discrete litigation expense accrual adjustment and updated estimates for tariffs. Projected full year comparable operating profit margin expansion is maintained at 30 - 80 basis points. While uncertainty remains on trade policies, estimates include tariffs on internationally sourced materials, based on current U.S. pronouncements, and estimates for China's retaliatory tariffs.

    The Company updated its EPS outlook range to $11.93 - $12.43, incorporating a $0.19 increase, reflecting $0.11 in favorable adjustments to foreign exchange estimates and $0.08 benefit from the discrete litigation expense accrual adjustment. The updated EPS growth outlook is 12% - 17% as reported, including a ~1% growth benefit from the discrete litigation expense accrual adjustment, while maintaining consistent 8% - 12% growth on a comparable basis.

    The following table provides the Company's updated outlook for annual key financial metrics in 2025 with a comparison to the prior outlook:

    Amounts in millions except per share data and percentages

     

    2025 Growth and Financial Performance Outlook

     

     

     

     

     

     

     

     

     

     

    Updated

     

    Prior

    Revenue

     

    $4,095

    -

    $4,210

     

    $4,055

    -

    $4,170

    Reported growth

     

    5%

    -

    8%

     

    4%

    -

    7%

    Organic growth

     

    6%

    -

    9%

     

    6%

    -

    9%

    CAG Diagnostics Recurring Revenue Growth

     

     

     

     

     

     

     

     

    Reported growth

     

    4%

    -

    7%

     

    3%

    -

    6%

    Organic growth

     

    5%

    -

    8%

     

    5%

    -

    8%

    Operating Margin

     

    31.1%

    -

    31.6%

     

    31.0%

    -

    31.5%

    Operating margin expansion

     

    210 bps

    -

    260 bps

     

    200 bps

    -

    250 bps

    Comparable margin expansion

     

    30 bps

    -

    80 bps

     

    30 bps

    -

    80 bps

    EPS

     

    $11.93

    -

    $12.43

     

    $11.74

    -

    $12.24

    Reported growth

     

    12%

    -

    17%

     

    10%

    -

    15%

    Comparable growth

     

    8%

    -

    12%

     

    8%

    -

    12%

    Other Key Metrics

     

     

     

     

     

     

     

     

    Net interest expense

     

    ~ $42

     

    ~ $42

    Share-based compensation tax benefit

     

    ~ $8

     

    ~ $8

    Share-based compensation tax rate benefit

     

    ~ 1%

     

    ~ 1%

    Effective tax rate

     

    ~ 21.5%

     

    ~ 21.5%

    Share-based compensation EPS impact

     

    ~ $0.10

     

    ~ $0.10

    Reduction in average shares outstanding

     

    2%

    -

    3%

     

    2%

    -

    3%

    Operating Cash Flow (% of Net Income)

     

    95%

    -

    105%

     

    100%

    -

    110%

    Free Cash Flow (% of Net Income)

     

    80%

    -

    85%

     

    85%

    -

    90%

    Capital Expenditures

     

    ~ $160

     

    ~ $160

    The following table outlines estimates of foreign currency exchange rate impacts, net of foreign currency hedging transactions, and foreign currency exchange rate assumptions reflected in the above financial performance outlook for 2025.

    Estimated Foreign Currency Exchange Rate Impacts

     

    2025

     

     

     

     

     

    Revenue growth rate impact

     

    (~1%)

    CAG Diagnostics recurring revenue growth rate impact

     

    (~1%)

    Operating margin growth impact

     

    ~ 0 bps

    EPS impact

     

    (~ $0.10)

    EPS growth impact

     

    (~ 1%)

     

     

     

     

     

    Go-Forward Foreign Currency Exchange Rate Assumptions

     

    2025

    In U.S. dollars

     

     

     

     

    euro

     

    $1.08

    British pound

     

    $1.25

    Canadian dollar

     

    $0.69

    Australian dollar

     

    $0.59

    Relative to the U.S. dollar

     

     

     

     

    Japanese yen

     

    ¥148

    Chinese renminbi

     

    ¥7.35

    Brazilian real

     

    R$6.18

    Conference Call and Webcast Information

    IDEXX Laboratories, Inc. will be hosting a conference call today at 8:30 a.m. (EDT) to discuss its first quarter 2025 results and management's outlook. Individuals can access a live webcast of the conference call through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the webcast will be available after 1:00 p.m. (EDT) on that day via the same link and will remain available for one year. The live call also will be accessible by telephone. To listen to the live conference call, please dial 1-800-289-0462 or 1-323-794-2442 and reference passcode 949516.

    2025 Annual Meeting of Shareholders

    IDEXX Laboratories, Inc. will hold its 2025 Annual Meeting of Shareholders (the "2025 Annual Meeting") on Wednesday, May 7, 2025 at 10:00 a.m. (EDT). The 2025 Annual Meeting will be a virtual meeting via a live audio webcast at www.virtualshareholdermeeting.com/IDXX2025. The online pre-meeting forum can be accessed before the 2025 Annual Meeting at www.proxyvote.com. At this online pre-meeting forum, you can submit questions in writing in advance of the 2025 Annual Meeting, vote, view the Rules of Conduct and Procedures relating to the 2025 Annual Meeting and access copies of the Company's proxy materials and annual report.

    Shareholders as of the close of business on March 10, 2025 are entitled to attend the 2025 Annual Meeting, vote their shares electronically and submit questions before and during the live audio webcast. As part of the 2025 Annual Meeting, the Company will answer the questions submitted by our shareholders during a live Q&A session, as time permits. The Company will publish the answer to each question, including those which we are unable to address during the meeting due to time constraints during the 2025 Annual Meeting, on the Company's Investor Relations website as soon as practicable after the meeting. An archived replay will also be available at www.virtualshareholdermeeting.com/IDXX2025 after the conclusion of the 2025 Annual Meeting. Further information on the 2025 Annual Meeting can be found in the Company's proxy materials.

    About IDEXX Laboratories, Inc.

    IDEXX is a global leader in pet healthcare innovation. Our diagnostic and software products and services create clarity in the complex, constantly evolving world of veterinary medicine. We support longer, fuller lives for pets by delivering insights and solutions that help the veterinary community around the world make confident decisions—to advance medical care, improve efficiency, and build thriving practices. Our innovations also help ensure the safety of milk and water across the world and maintain the health and well-being of people and livestock. IDEXX Laboratories, Inc. is a member of the S&P 500® Index. Headquartered in Maine, IDEXX employs approximately 11,000 people and offers solutions and products to customers in more than 175 countries and territories. For more information about IDEXX, visit www.idexx.com.

    Note Regarding Forward-Looking Statements

    This earnings release and the statements to be made in the accompanying earnings conference call contain forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including statements about the Company's business prospects and estimates of the Company's financial results for future periods. Forward-looking statements are included above under "2025 Growth and Financial Performance Outlook" and elsewhere and can be identified by the use of words such as "expects", "may", "anticipates", "intends", "would", "will", "plans", "believes", "estimates", "projected", "should", and similar words and expressions. Our forward-looking statements include statements relating to our expectations regarding financial performance; revenue growth and EPS outlooks; operating and free cash flow forecast; projected impact of foreign currency exchange rates and interest rates; projected operating margins and expenses and capital expenditures; projected tax, tax rate and EPS benefits from share-based compensation arrangements; projected effective tax rates, reduction of average shares outstanding and net interest expense; projected impact of tariffs (including U.S. tariffs and China's retaliatory tariffs); trends and other factors impacting the pet healthcare industry; net price realization improvement; IDEXX inVue DxTM analyzer placements; and future product launches and menu expansions. These statements are intended to provide management's expectation of future events as of the date of this earnings release; are based on management's estimates, projections, beliefs, and assumptions as of the date of this earnings release; and are not guarantees of future performance. These forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, among other things, the matters described under the headings "Business," "Risk Factors," "Legal Proceedings," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Quantitative and Qualitative Disclosures About Market Risk" in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 and in the corresponding sections of the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, as well as those described from time to time in the Company's other filings with the U.S. Securities and Exchange Commission available at www.sec.gov. The Company specifically disclaims any obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

    Statement Regarding Non-GAAP Financial Measures

    The following defines terms and conventions and provides reconciliations regarding certain measures used in this earnings release and/or the accompanying earnings conference call that are not required by, or presented in accordance with, generally accepted accounting principles in the United States of America ("GAAP"), otherwise referred to as non-GAAP financial measures. To supplement the Company's consolidated results presented in accordance with GAAP, the Company has disclosed non-GAAP financial measures that exclude or adjust certain items. Management believes these non-GAAP financial measures provide useful supplemental information for its and investors' evaluation of the Company's business performance and liquidity and are useful for period-over-period comparisons of the performance of the Company's business and its liquidity and to the performance and liquidity of our peers. While management believes that these non-GAAP financial measures are useful in evaluating the Company's business, this information should be considered as supplemental in nature and should not be considered in isolation or as a substitute for the related financial information prepared in accordance with GAAP. In addition, these non-GAAP financial measures may not be the same as similarly titled measures reported by other companies.

    Constant currency - Constant currency references are non-GAAP financial measures which exclude the impact of changes in foreign currency exchange rates and are consistent with how management evaluates our performance and comparisons with prior and future periods. We estimated the net impacts of currency on our revenue, gross profit, operating profit, and EPS results by restating results to the average exchange rates or exchange rate assumptions for the comparative period, which includes adjusting for the estimated impacts of foreign currency hedging transactions and certain impacts on our effective tax rates. These estimated currency changes impacted first quarter 2025 results as follows: decreased gross profit growth by 1.2%, increased gross margin growth by 10 basis points, decreased operating expense growth by 1.0%, decreased operating profit growth by 1.4%, increased operating profit margin growth by an immaterial amount , and decreased EPS growth by 1.4%. Constant currency revenue growth represents the percentage change in revenue during the applicable period, as compared to the prior year period, excluding the impact of changes in foreign currency exchange rates. See the supplementary analysis of results below for revenue percentage change from currency for the three months ended March 31, 2025 and refer to the 2025 Growth and Financial Performance Outlook section of this earnings release for estimated foreign currency exchange rate impacts on 2025 projections and estimates.

    Growth and organic revenue growth - All references to growth and organic growth refer to growth compared to the equivalent prior year period unless specifically noted. Organic revenue growth is a non-GAAP financial measure that represents the percent change in revenue, as compared to the same period for the prior year, net of the impact of changes in foreign currency exchange rates, certain business acquisitions, and divestitures. Management believes that reporting organic revenue growth provides useful information to investors by facilitating easier comparisons of our revenue performance with prior and future periods and to the performance of our peers. Organic revenue growth should be considered in addition to, and not as a replacement of or a superior measure to, revenue growth reported in accordance with GAAP. See the supplementary analysis of results below for a reconciliation of reported revenue growth to organic revenue growth for the three months ended March 31, 2025. Please refer to the constant currency note above for a summary of foreign currency exchange rate impacts. Please refer to the 2025 Growth and Financial Performance Outlook section of this earnings release for estimated full year 2025 organic revenue growth for the Company and CAG Diagnostics recurring revenue growth. The percentage change in revenue resulting from acquisitions represents revenues during the current year period, limited to the initial 12 months from the date of the acquisition, that are directly attributable to business acquisitions. Revenue from acquisitions is expected to benefit projected full year 2025 revenue growth by an immaterial amount and have no impact on CAG Diagnostics recurring revenue growth.

    Comparable growth metrics - Comparable gross profit growth, comparable gross margin gain (or growth), comparable operating expense growth, comparable operating profit growth and comparable operating margin gain (or growth) are non-GAAP financial measures and exclude the impact of changes in foreign currency exchange rates and non-recurring or unusual items (if any). Please refer to the constant currency note above for a summary of foreign currency exchange rate impacts. Management believes that reporting comparable gross profit growth, comparable gross margin gain (or growth), comparable operating expense growth, comparable operating profit growth and comparable operating margin gain (or growth) provides useful information to investors because it enables better period-over-period comparisons of the fundamental financial results by excluding items that vary independent of performance and provides greater transparency to investors regarding key metrics used by management. Comparable gross profit growth, comparable gross margin gain (or growth), comparable operating expense growth, comparable operating profit growth and comparable operating margin gain (or growth) should be considered in addition to, and not as replacements of or superior measures to, gross profit growth, gross margin gain, operating expense growth, operating profit growth and operating margin gain reported in accordance with GAAP.

    The reconciliation of these non-GAAP financial measures is as follows:

     

     

    Three Months Ended

    Year-over-Year

     

     

    March 31,

     

    March 31,

    Change

    Dollar amounts in thousands

     

    2025

     

    2024

     

    Gross Profit (as reported)

     

    $

    623,379

     

     

    $

    593,070

     

    5 %

    Gross margin

     

     

    62.4

    %

     

     

    61.5

    %

    90 bps

    Less: comparability adjustments

     

     

     

     

     

    Change from currency

     

     

    (6,907

    )

     

     

    —

     

     

    Comparable gross profit growth

     

    $

    630,286

     

     

    $

    593,070

     

    6 %

    Comparable gross margin and gross margin gain (or growth)

     

     

    62.4

    %

     

     

    61.5

    %

    80 bps

     

     

     

     

     

     

    Operating expenses (as reported)

     

    $

    306,845

     

     

    $

    294,112

     

    4 %

    Less: comparability adjustments

     

     

     

     

     

    Change from currency

     

     

    (2,819

    )

     

     

    —

     

     

    Now-concluded litigation matter

     

     

    (8,600

    )

     

     

    —

     

     

    Comparable operating expense growth

     

    $

    318,264

     

     

    $

    294,112

     

    8 %

     

     

     

     

     

     

    Income from operations (as reported)

     

    $

    316,534

     

     

    $

    298,958

     

    6 %

    Operating margin

     

     

    31.7

    %

     

     

    31.0

    %

    70 bps

    Less: comparability adjustments

     

     

     

     

     

    Change from currency

     

     

    (4,088

    )

     

     

    —

     

     

    Now-concluded litigation matter

     

     

    8,600

     

     

     

    —

     

     

    Comparable operating profit growth

     

    $

    312,022

     

     

    $

    298,958

     

    4 %

    Comparable operating margin and operating margin gain (or growth)

     

     

    30.9

    %

     

     

    31.0

    %

    (10 ) bps

    Amounts presented may not recalculate due to rounding.

    Projected 2025 comparable operating margin expansion outlined in the 2025 Growth and Financial Performance Outlook section of this earnings release reflects adjustments to projected 2025 operating margin expansion for: (i) an immaterial impact from year-over-year foreign currency exchange rate changes at noted exchange rates; and (ii) positive impact of the approximately $9 million discrete litigate expense accrual adjustment in the first quarter of 2025; and (iii) adjustment to full year 2024 reported operating margin expansion for the negative impact of the $61.5 million discrete litigation expense accrual adjustment in the second quarter of 2024.

    These impacts described above reconcile reported gross profit growth, gross margin gain, operating expense growth, operating profit growth and operating margin gain (including projected 2025 operating margin expansion) to comparable gross profit growth, comparable gross margin gain, comparable operating expense growth, comparable operating profit growth and comparable operating margin gain for the Company.

    Comparable EPS growth - Comparable EPS growth is a non-GAAP financial measure that represents the percentage change in earnings per share (diluted) ("EPS") for a measurement period, as compared to the prior base period, net of the impact of changes in foreign currency exchange rates from the prior base period and excluding the tax benefits of share-based compensation activity under ASU 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, and non-recurring or unusual items (if any). Management believes comparable EPS growth is a more useful way to measure the Company's business performance than EPS growth because it enables better period-over-period comparisons of the fundamental financial results by excluding items that vary independent of performance and provides greater transparency to investors regarding a key metric used by management. Comparable EPS growth should be considered in addition to, and not as a replacement of or a superior measure to, EPS growth reported in accordance with GAAP. Please refer to the constant currency note above for a summary of foreign currency exchange rate impacts.

    The reconciliation of this non-GAAP financial measure is as follows:

     

     

    Three Months Ended

     

    Year-over-Year

     

     

    March 31,

     

    March 31,

     

    Growth

     

     

    2025

     

    2024

     

     

    Earnings per share (diluted)

     

    $

    2.96

     

     

    $

    2.81

     

    5%

    Less: comparability adjustments

     

     

     

     

     

     

    Share-based compensation activity

     

     

    0.01

     

     

     

    0.10

     

     

    Now-concluded litigation matter

     

     

    0.08

     

     

     

    —

     

     

    Change from currency

     

     

    (0.04

    )

     

     

    —

     

     

    Comparable EPS growth

     

    $

    2.91

     

     

    $

    2.71

     

    7%

    Amounts presented may not recalculate due to rounding.

    Projected 2025 comparable EPS growth outlined in the 2025 Growth and Financial Performance Outlook section of this earnings release reflects adjustments to projected full year 2025 reported EPS for: (i) estimated positive share-based compensation activity of ~$0.10; and (ii) estimated negative year-over-year foreign currency exchange rate change impact of ~$0.10 at noted exchange rates; (iii) impact of the discrete litigation expense accrual adjustment of $0.08 in the first quarter of 2025; (iv) adjustment to full year 2024 reported EPS for a negative $0.56 impact from the discrete litigation expense accrual adjustment in the second quarter of 2024; and (v) positive impact of share-based compensation activity of ~$0.24.

    These impacts and those described in the constant currency note above reconcile reported EPS growth (including projected 2025 reported EPS growth) to comparable EPS growth for the Company.

    Segment Income from Operations - We report segment income from operations in our Segment Information table below. Segment income from operations is a non-GAAP financial measure that adjusts for the impact of foreign currency transaction gains and losses and should be considered in addition to, and not as a replacement for, income from operations. We exclude foreign currency transaction gains and losses for each reportable segment (CAG, Water, and LPD) from segment income from operations and report the full amount of foreign currency transaction gains and losses in our Other operating segment. We believe that reporting segment income from operations provides supplemental analysis to help investors further evaluate each reportable segment's business performance by excluding foreign currency transaction gains and losses, which are centrally managed by our corporate treasury function and which we do not consider relevant for assessing the results of each reportable segment's operations. In addition, we believe that reporting segment income from operations provides information to investors regarding key metrics that are used by management, including our chief operating decision-maker, in evaluating the performance of each reportable segment.

    The reconciliation of this non-GAAP financial measure is as follows:

    Amounts in thousands

     

    For the Three Months Ended March 31,

     

     

    2025

     

    2024

     

     

    Income from

    Operations

     

    Impact from

    Foreign

    Currency

     

    Segment

    Income from

    Operations

     

    Income from

    Operations

     

    Impact from

    Foreign

    Currency

     

    Segment

    Income from

    Operations

    CAG

     

    $

    294,572

     

    $

    583

     

     

    $

    295,155

     

    $

    278,886

     

     

    $

    810

     

     

    $

    279,696

     

    Water

     

     

    20,774

     

     

    43

     

     

     

    20,817

     

     

    19,372

     

     

     

    58

     

     

     

    19,430

     

    LPD

     

     

    80

     

     

    45

     

     

     

    125

     

     

    801

     

     

     

    65

     

     

     

    866

     

    Other

     

     

    1,108

     

     

    (671

    )

     

     

    437

     

     

    (101

    )

     

     

    (933

    )

     

     

    (1,034

    )

    Total

     

    $

    316,534

     

    $

    —

     

     

    $

    316,534

     

    $

    298,958

     

     

    $

    —

     

     

    $

    298,958

     

    Free cash flow - Free cash flow is a non-GAAP financial measure and means, with respect to a measurement period, the cash generated from operations during that period, reduced by the Company's investments in property and equipment. Management believes free cash flow is a useful measure because it indicates the cash the operations of the business are generating after appropriate reinvestment for recurring investments in property and equipment that are required to operate the business. Free cash flow should be considered in addition to, and not as a replacement of or a superior measure to, net cash provided by operating activities. See the supplementary analysis of results below for our calculation of free cash flow for the three months ended March 31, 2025 and 2024. To estimate projected 2025 free cash flow, we have deducted projected purchases of property and equipment (also referred to as capital expenditures) of approximately $160 million. Free cash flow conversion, or the net income to free cash flow ratio, is a non-GAAP financial measure that is defined as free cash flow, with respect to a measurement period, divided by net income for the same period. To calculate trailing twelve-month net income to free cash flow ratio for the twelve months ended March 31, 2025, we have deducted purchases of property and equipment of approximately $121 million from net cash provided from operating activities of approximately $968 million, divided by net income of approximately $895 million.

    Debt to Adjusted EBITDA (Leverage Ratios) - Adjusted EBITDA, gross debt, and net debt are non-GAAP financial measures. Adjusted EBITDA is a non-GAAP financial measure of earnings before interest, taxes, depreciation, amortization, non-recurring transaction expenses incurred in connection with acquisitions, share-based compensation expense, and certain other non-cash losses and charges. Management believes that reporting Adjusted EBITDA, gross debt, and net debt in the Debt to Adjusted EBITDA ratios provides supplemental analysis to help investors further evaluate the Company's business performance and available borrowing capacity under the Company's credit facility. Adjusted EBITDA, gross debt, and net debt should be considered in addition to, and not as replacements of or superior measures to, net income or total debt reported in accordance with GAAP. For further information on how Adjusted EBITDA and the Debt to Adjusted EBITDA Ratios are calculated, see the Company's Annual Report on Form 10-K for the year ended December 31, 2024 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2025.

    Notes and Definitions

    Discrete litigation expense accrual - During the first quarter of 2025, the Company reduced its previously established $89.0 million accrual related to a now-concluded litigation matter by approximately $9 million, resulting in a total accrual for this now-concluded litigation matter of approximately $80 million as of March 31, 2025, which represented our best estimate of the amount of the loss.

    Now-concluded litigation matter - The Company was a defendant in a litigation matter involving an alleged breach of contract for underpayment of royalty payments made from 2004 through 2017 under an expired patent license agreement, and the trial court ruled in favor of the plaintiff in 2020. Following appeals and in light of the appellate court's April 3, 2025 decision, on April 17, 2025, the Company paid the judgment of approximately $80 million, and the plaintiff executed a satisfaction and release of judgment, which was filed with the trial court, concluding this matter. For further information, see the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025.

    IDEXX Laboratories, Inc. and Subsidiaries

     

     

     

    Condensed Consolidated Statement of Operations

     

     

     

    Amounts in thousands except per share data (Unaudited)

     

     

     

     

     

     

     

    Three Months Ended

     

     

     

     

    March 31,

     

    March 31,

     

     

     

     

    2025

     

    2024

    Revenue:

     

    Revenue

     

    $

    998,427

     

     

    $

    964,095

     

    Expenses and Income:

     

    Cost of revenue

     

     

    375,048

     

     

     

    371,025

     

     

     

    Gross profit

     

     

    623,379

     

     

     

    593,070

     

     

     

    Sales and marketing

     

     

    156,223

     

     

     

    149,453

     

     

     

    General and administrative

     

     

    91,561

     

     

     

    92,024

     

     

     

    Research and development

     

     

    59,061

     

     

     

    52,635

     

     

     

    Total operating expense

     

     

    306,845

     

     

     

    294,112

     

     

     

    Income from operations

     

     

    316,534

     

     

     

    298,958

     

     

     

    Interest expense, net

     

     

    (6,450

    )

     

     

    (3,479

    )

     

     

    Income before provision for income taxes

     

     

    310,084

     

     

     

    295,479

     

     

     

    Provision for income taxes

     

     

    67,407

     

     

     

    59,900

     

    Net Income:

     

    Net income attributable to stockholders

     

    $

    242,677

     

     

    $

    235,579

     

     

     

    Earnings per share: Basic

     

    $

    2.98

     

     

    $

    2.84

     

     

     

    Earnings per share: Diluted

     

    $

    2.96

     

     

    $

    2.81

     

     

     

    Shares outstanding: Basic

     

     

    81,319

     

     

     

    83,096

     

     

     

    Shares outstanding: Diluted

     

     

    81,922

     

     

     

    83,957

     

    IDEXX Laboratories, Inc. and Subsidiaries

     

     

     

    Selected Operating Information (Unaudited)

     

     

     

     

     

     

     

    Three Months Ended

     

     

     

     

    March 31,

     

    March 31,

     

     

     

     

    2025

     

    2024

    Operating Ratios

     

    Gross profit

     

    62.4

    %

     

    61.5

    %

    (as a percentage of revenue):

     

    Sales, marketing, general and administrative expense

     

    24.8

    %

     

    25.0

    %

     

     

    Research and development expense

     

    5.9

    %

     

    5.5

    %

     

     

    Income from operations1

     

    31.7

    %

     

    31.0

    %

     

     

     

     

     

     

     

    1Amounts presented may not recalculate due to rounding.

    IDEXX Laboratories, Inc. and Subsidiaries

     

     

     

     

    Segment Information

     

     

     

     

    Amounts in thousands (Unaudited)

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Three Months Ended

     

     

     

     

    March 31,

    2025

     

    Percent of

    Revenue

     

    March 31,

    2024

     

    Percent of

    Revenue

     

     

     

     

     

     

     

    Revenue:

     

    CAG

     

    $

    919,836

     

     

     

    $

    889,285

     

     

     

     

     

    Water

     

     

    45,321

     

     

     

     

    43,071

     

     

     

     

     

    LPD

     

     

    28,596

     

     

     

     

    28,205

     

     

     

     

     

    Other

     

     

    4,674

     

     

     

     

    3,534

     

     

     

     

     

    Total

     

    $

    998,427

     

     

     

    $

    964,095

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Gross Profit:

     

    CAG

     

    $

    574,823

     

    62.5

    %

     

    $

    546,236

     

     

    61.4

    %

     

     

    Water

     

     

    32,073

     

    70.8

    %

     

     

    30,497

     

     

    70.8

    %

     

     

    LPD

     

     

    14,365

     

    50.2

    %

     

     

    15,234

     

     

    54.0

    %

     

     

    Other

     

     

    2,118

     

    45.3

    %

     

     

    1,103

     

     

    31.2

    %

     

     

    Total

     

    $

    623,379

     

    62.4

    %

     

    $

    593,070

     

     

    61.5

    %

     

     

     

     

     

     

     

     

     

     

     

    Income from Operations:

     

    CAG

     

    $

    295,155

     

    32.1

    %

     

    $

    279,696

     

     

    31.5

    %

     

     

    Water

     

     

    20,817

     

    45.9

    %

     

     

    19,430

     

     

    45.1

    %

     

     

    LPD

     

     

    125

     

    0.4

    %

     

     

    866

     

     

    3.1

    %

     

     

    Other

     

     

    437

     

    9.3

    %

     

     

    (1,034

    )

     

    (29.3

    )%

     

     

    Total

     

    $

    316,534

     

    31.7

    %

     

    $

    298,958

     

     

    31.0

    %

    IDEXX Laboratories, Inc. and Subsidiaries

    Revenues and Revenue Growth Analysis by Product and Service Categories and by Domestic and International Markets

    Amounts in thousands (Unaudited)

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Three Months Ended

     

     

     

     

     

     

     

     

     

     

     

     

    March 31,

    2025

     

    March 31,

    2024

     

    Dollar

    Change

     

    Reported

    Revenue

    Growth1

     

    Percentage

    Change from

    Currency

     

    Percentage

    Change from

    Acquisitions

     

    Organic

    Revenue

    Growth1

    Net Revenue

     

     

     

     

     

     

     

    CAG

     

    $

    919,836

     

    $

    889,285

     

    $

    30,551

     

     

    3.4

    %

     

    (1.1

    )%

     

    0.2

    %

     

    4.4

    %

    United States

     

     

    623,889

     

     

    602,195

     

     

    21,694

     

     

    3.6

    %

     

    —

     

     

    0.2

    %

     

    3.4

    %

    International

     

     

    295,947

     

     

    287,090

     

     

    8,857

     

     

    3.1

    %

     

    (3.6

    )%

     

    —

     

     

    6.7

    %

    Water

     

     

    45,321

     

     

    43,071

     

     

    2,250

     

     

    5.2

    %

     

    (2.1

    )%

     

    —

     

     

    7.3

    %

    United States

     

     

    23,503

     

     

    22,199

     

     

    1,304

     

     

    5.9

    %

     

    —

     

     

    —

     

     

    5.9

    %

    International

     

     

    21,818

     

     

    20,872

     

     

    946

     

     

    4.5

    %

     

    (4.4

    )%

     

    —

     

     

    8.9

    %

    LPD

     

     

    28,596

     

     

    28,205

     

     

    391

     

     

    1.4

    %

     

    (2.8

    )%

     

    —

     

     

    4.2

    %

    United States

     

     

    5,788

     

     

    5,164

     

     

    624

     

     

    12.1

    %

     

    —

     

     

    —

     

     

    12.1

    %

    International

     

     

    22,808

     

     

    23,041

     

     

    (233

    )

     

    (1.0

    %)

     

    (3.4

    )%

     

    —

     

     

    2.4

    %

    Other

     

     

    4,674

     

     

    3,534

     

     

    1,140

     

     

    32.2

    %

     

    —

     

     

    —

     

     

    32.2

    %

    Total Company

     

    $

    998,427

     

    $

    964,095

     

    $

    34,332

     

     

    3.6

    %

     

    (1.2

    )%

     

    0.1

    %

     

    4.7

    %

    United States

     

     

    654,861

     

     

    631,009

     

     

    23,852

     

     

    3.8

    %

     

    —

     

     

    0.2

    %

     

    3.6

    %

    International

     

     

    343,566

     

     

    333,086

     

     

    10,480

     

     

    3.1

    %

     

    (3.6

    )%

     

    —

     

     

    6.8

    %

     

     

     

    Three Months Ended

     

     

     

     

     

     

     

     

     

     

     

     

    March 31,

    2025

     

    March 31,

    2024

     

    Dollar

    Change

     

    Reported

    Revenue

    Growth1

     

    Percentage

    Change from

    Currency

     

    Percentage

    Change from

    Acquisitions

     

    Organic

    Revenue

    Growth1

    Net CAG Revenue

     

     

     

     

     

     

     

    CAG Diagnostics recurring revenue:

     

    $

    806,267

     

    $

    780,144

     

    $

    26,123

     

     

    3.3

    %

     

    (1.2

    )%

     

    —

     

     

    4.5

    %

    IDEXX VetLab consumables

     

     

    344,779

     

     

    316,929

     

     

    27,850

     

     

    8.8

    %

     

    (1.7

    )%

     

    —

     

     

    10.5

    %

    Rapid assay products

     

     

    84,034

     

     

    86,315

     

     

    (2,281

    )

     

    (2.6

    )%

     

    (0.7

    )%

     

    —

     

     

    (1.9

    )%

    Reference laboratory diagnostic and consulting services

     

     

    344,406

     

     

    344,338

     

     

    68

     

     

    —

     

     

    (0.8

    )%

     

    —

     

     

    0.9

    %

    CAG Diagnostics services and accessories

     

     

    33,048

     

     

    32,562

     

     

    486

     

     

    1.5

    %

     

    (1.5

    )%

     

    —

     

     

    3.0

    %

    CAG Diagnostics capital – instruments

     

     

    31,994

     

     

    34,092

     

     

    (2,098

    )

     

    (6.2

    )%

     

    (1.5

    )%

     

    —

     

     

    (4.6

    )%

    Veterinary software, services and diagnostic imaging systems:

     

     

    81,575

     

     

    75,049

     

     

    6,526

     

     

    8.7

    %

     

    (0.5

    )%

     

    1.8

    %

     

    7.5

    %

    Recurring revenue

     

     

    65,793

     

     

    59,700

     

     

    6,093

     

     

    10.2

    %

     

    (0.6

    )%

     

    1.8

    %

     

    9.0

    %

    Systems and hardware

     

     

    15,782

     

     

    15,349

     

     

    433

     

     

    2.8

    %

     

    (0.5

    )%

     

    1.6

    %

     

    1.6

    %

    Net CAG revenue

     

    $

    919,836

     

    $

    889,285

     

    $

    30,551

     

     

    3.4

    %

     

    (1.1

    )%

     

    0.2

    %

     

    4.4

    %

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Three Months Ended

     

     

     

     

     

     

     

     

     

     

     

     

    March 31,

    2025

     

    March 31,

    2024

     

    Dollar

    Change

     

    Reported

    Revenue

    Growth1

     

    Percentage

    Change from

    Currency

     

    Percentage

    Change from

    Acquisitions

     

    Organic

    Revenue

    Growth1

     

     

     

     

     

     

     

     

    CAG Diagnostics recurring revenue:

     

    $

    806,267

     

    $

    780,144

     

    $

    26,123

     

    3.3

    %

     

    (1.2

    )%

     

    —

     

    4.5

    %

    United States

     

     

    536,977

     

     

    523,041

     

     

    13,936

     

    2.7

    %

     

    —

     

     

    —

     

    2.7

    %

    International

     

     

    269,290

     

     

    257,103

     

     

    12,187

     

    4.7

    %

     

    (3.7

    )%

     

    —

     

    8.5

    %

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    1See Statements Regarding Non-GAAP Financial Measures, above. Amounts presented may not recalculate due to rounding.

    IDEXX Laboratories, Inc. and Subsidiaries

    Condensed Consolidated Balance Sheet

    Amounts in thousands (Unaudited)

     

     

     

     

    March 31,

    2025

     

    December 31,

    2024

     

     

     

     

     

    Assets:

     

    Current Assets:

     

     

     

     

     

     

    Cash and cash equivalents

     

    $

    163,970

     

    $

    288,266

     

     

    Accounts receivable, net

     

     

    527,464

     

     

    473,575

     

     

    Inventories

     

     

    395,987

     

     

    381,877

     

     

    Other current assets

     

     

    230,192

     

     

    256,179

     

     

    Total current assets

     

     

    1,317,613

     

     

    1,399,897

     

     

    Property and equipment, net

     

     

    717,624

     

     

    713,123

     

     

    Other long-term assets, net

     

     

    1,178,452

     

     

    1,180,423

     

     

    Total assets

     

    $

    3,213,689

     

    $

    3,293,443

    Liabilities and Stockholders'

     

     

     

     

     

     

    Equity:

     

    Current Liabilities:

     

     

     

     

     

     

    Accounts payable

     

    $

    120,096

     

    $

    114,211

     

     

    Accrued liabilities

     

     

    490,688

     

     

    502,119

     

     

    Line of credit

     

     

    319,500

     

     

    250,000

     

     

    Current portion of long-term debt

     

     

    170,929

     

     

    167,787

     

     

    Deferred revenue

     

     

    35,000

     

     

    33,799

     

     

    Total current liabilities

     

     

    1,136,213

     

     

    1,067,916

     

     

    Long-term debt, net of current portion

     

     

    449,799

     

     

    449,786

     

     

    Other long-term liabilities, net

     

     

    179,664

     

     

    180,428

     

     

    Total long-term liabilities

     

     

    629,463

     

     

    630,214

     

     

    Total stockholders' equity

     

     

    1,448,013

     

     

    1,595,313

     

     

    Total liabilities and stockholders' equity

     

    $

    3,213,689

     

    $

    3,293,443

    IDEXX Laboratories, Inc. and Subsidiaries

    Selected Balance Sheet Information (Unaudited)

     

     

     

     

    March 31,

    2025

     

    December 31,

    2024

     

    September 30,

    2024

     

    June 30,

    2024

     

    March 31,

    2024

    Selected Balance Sheet Information:

     

    Days sales outstanding1

     

    45.7

     

    47.1

     

    48.9

     

    47.3

     

    45.7

     

     

    Inventory turns2

     

    1.3

     

    1.3

     

    1.3

     

    1.4

     

    1.3

     

     

     

     

     

     

     

     

     

     

     

     

     

    1Days sales outstanding represents the average of the accounts receivable balances at the beginning and end of each quarter divided by revenue for that quarter, the result of which is then multiplied by 91.25 days.

    2Inventory turns are calculated as the ratio of our inventory-related cost of revenue for the quarter multiplied by four, divided by the average inventory balances at the beginning and end of each quarter.

    IDEXX Laboratories, Inc. and Subsidiaries

    Condensed Consolidated Statement of Cash Flows

    Amounts in thousands (Unaudited)

     

     

     

     

    Three Months Ended

     

     

     

     

    March 31,

    2025

     

    March 31,

    2024

     

     

     

     

     

    Operating:

     

    Cash Flows from Operating Activities:

     

     

     

     

     

     

    Net income

     

    $

    242,677

     

     

    $

    235,579

     

     

     

    Non-cash adjustments to net income

     

     

    55,972

     

     

     

    44,422

     

     

     

    Changes in assets and liabilities

     

     

    (60,687

    )

     

     

    (81,416

    )

     

     

    Net cash provided by operating activities

     

     

    237,962

     

     

     

    198,585

     

    Investing:

     

    Cash Flows from Investing Activities:

     

     

     

     

     

     

    Purchases of property and equipment

     

     

    (30,026

    )

     

     

    (30,273

    )

     

     

    Acquisition of a business

     

     

    —

     

     

     

    (77,000

    )

     

     

    Proceeds from net investment hedges

     

     

    416

     

     

     

    329

     

     

     

    Net cash used by investing activities

     

     

    (29,610

    )

     

     

    (106,944

    )

    Financing:

     

    Cash Flows from Financing Activities:

     

     

     

     

     

     

    Repayments under credit facility, net

     

     

    69,500

     

     

     

    —

     

     

     

    Repurchases of common stock

     

     

    (400,890

    )

     

     

    (154,764

    )

     

     

    Proceeds from exercises of stock options and employee stock purchase plans

     

     

    7,193

     

     

     

    20,879

     

     

     

    Shares withheld for statutory tax withholding payments on restricted stock

     

     

    (6,124

    )

     

     

    (10,189

    )

     

     

    Net cash used by financing activities

     

     

    (330,321

    )

     

     

    (144,074

    )

     

     

    Net effect of changes in exchange rates on cash

     

     

    (2,327

    )

     

     

    (4,066

    )

     

     

    Net decrease in cash and cash equivalents

     

     

    (124,296

    )

     

     

    (56,499

    )

     

     

    Cash and cash equivalents, beginning of period

     

     

    288,266

     

     

     

    453,932

     

     

     

    Cash and cash equivalents, end of period

     

    $

    163,970

     

     

    $

    397,433

     

    IDEXX Laboratories, Inc. and Subsidiaries

    Free Cash Flow

    Amounts in thousands (Unaudited)

     

     

     

     

    Three Months Ended

     

     

     

     

    March 31,

    2025

     

    March 31,

    2024

     

     

     

     

     

    Free Cash Flow:

     

    Net cash provided by operating activities

     

    $

    237,962

     

     

    $

    198,585

     

     

     

    Investing cash flows attributable to purchases of property and equipment

     

     

    (30,026

    )

     

     

    (30,273

    )

     

     

    Free cash flow1

     

    $

    207,936

     

     

    $

    168,312

     

     

     

     

     

     

     

     

    1See Statements Regarding Non-GAAP Financial Measures, above.

    IDEXX Laboratories, Inc. and Subsidiaries

     

     

     

    Common Stock Repurchases

     

     

     

    Amounts in thousands except per share data (Unaudited)

     

     

     

     

     

    Three Months Ended

     

     

    March 31,

    2025

     

    March 31,

    2024

     

     

     

    Shares repurchased in the open market

     

     

    931

     

     

    303

    Shares acquired through employee surrender for statutory tax withholding

     

     

    14

     

     

    18

    Total shares repurchased

     

     

    945

     

     

    321

     

     

     

     

     

    Cost of shares repurchased in the open market

     

    $

    409,215

     

    $

    167,102

    Cost of shares for employee surrenders

     

     

    6,124

     

     

    10,189

    Total cost of shares

     

    $

    415,339

     

    $

    177,291

     

     

     

     

     

    Average cost per share – open market repurchases

     

    $

    439.64

     

    $

    550.90

    Average cost per share – employee surrenders

     

    $

    444.52

     

    $

    560.56

    Average cost per share – total

     

    $

    439.71

     

    $

    551.45

     

     

     

     

     

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250430490568/en/

    John Ravis, Investor Relations, 1-207-556-8155

    Get the next $IDXX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IDXX

    DatePrice TargetRatingAnalyst
    12/2/2024$500.00Outperform
    Leerink Partners
    7/25/2024$580.00Buy
    BTIG Research
    1/30/2024$525.00Overweight → Neutral
    Piper Sandler
    12/7/2023$602.00Outperform
    Exane BNP Paribas
    12/4/2023Neutral → Buy
    Cleveland Research
    8/2/2023$610.00Overweight → Neutral
    Atlantic Equities
    7/25/2022$415.00Buy → Hold
    Stifel
    7/21/2022$530.00 → $435.00Neutral → Buy
    Goldman
    More analyst ratings

    $IDXX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • IDEXX Laboratories to Present at Stifel Conference and Announces 2025 Investor Day

      IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, today announced that Andrew Emerson, Executive Vice President and Chief Financial Officer, and Tina Hunt, Executive Vice President, Global Strategy and Commercial, will participate in a fireside chat at the Stifel Jaws & Paws Conference on Wednesday, May 28, 2025 from 10:55 am – 11:25 am (EDT). A live audio webcast of the presentation will be available through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the presentation will be available via the same link. 2025 Investor Day IDEXX Laboratories, Inc. also announced today that it will host its 2025 Investor Day on Thursday,

      5/13/25 2:30:00 PM ET
      $IDXX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • IDEXX Laboratories Announces First Quarter Results

      Achieves first quarter revenue growth of 4% as reported and 5% organic, supported by CAG Diagnostics recurring revenue growth of 3% as reported and 4.5% organic. Organic revenue growth supported by benefits from IDEXX execution drivers, including continued solid new business gains and strong year-over-year global premium instrument installed base growth, including over 300 IDEXX inVue Dx™ placements. Delivers EPS of $2.96, an increase of 5% as reported and 7% on a comparable basis, supported by gross margin expansion of 90 basis points as reported and 80 basis points on a comparable basis. Adjusts 2025 revenue guidance to $4,095 million - $4,210 million, an increase of $40 million

      5/1/25 6:30:00 AM ET
      $IDXX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • IDEXX Laboratories to Release 2025 First Quarter Financial Results

      IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2025 first quarter financial results for Thursday, May 1, 2025, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q1 2025 Earnings Snapshot through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the webcast will be available after 1:00 p.m. ET on that day via the same link and will remain available for one year. The live call also will be accessible by telephone. To listen to t

      4/3/25 1:30:00 PM ET
      $IDXX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $IDXX
    SEC Filings

    See more
    • SEC Form SD filed by IDEXX Laboratories Inc.

      SD - IDEXX LABORATORIES INC /DE (0000874716) (Filer)

      5/30/25 4:02:56 PM ET
      $IDXX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • IDEXX Laboratories Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - IDEXX LABORATORIES INC /DE (0000874716) (Filer)

      5/9/25 4:00:15 PM ET
      $IDXX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 10-Q filed by IDEXX Laboratories Inc.

      10-Q - IDEXX LABORATORIES INC /DE (0000874716) (Filer)

      5/1/25 4:11:17 PM ET
      $IDXX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $IDXX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by IDEXX Laboratories Inc.

      SC 13G/A - IDEXX LABORATORIES INC /DE (0000874716) (Subject)

      11/12/24 3:48:28 PM ET
      $IDXX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Amendment: SEC Form SC 13G/A filed by IDEXX Laboratories Inc.

      SC 13G/A - IDEXX LABORATORIES INC /DE (0000874716) (Subject)

      11/4/24 11:47:05 AM ET
      $IDXX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed by IDEXX Laboratories Inc. (Amendment)

      SC 13G/A - IDEXX LABORATORIES INC /DE (0000874716) (Subject)

      2/13/24 5:06:19 PM ET
      $IDXX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $IDXX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Leerink Partners initiated coverage on IDEXX Labs with a new price target

      Leerink Partners initiated coverage of IDEXX Labs with a rating of Outperform and set a new price target of $500.00

      12/2/24 6:57:33 AM ET
      $IDXX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • BTIG Research initiated coverage on IDEXX Labs with a new price target

      BTIG Research initiated coverage of IDEXX Labs with a rating of Buy and set a new price target of $580.00

      7/25/24 6:47:32 AM ET
      $IDXX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • IDEXX Labs downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded IDEXX Labs from Overweight to Neutral and set a new price target of $525.00

      1/30/24 6:59:50 AM ET
      $IDXX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $IDXX
    Financials

    Live finance-specific insights

    See more
    • IDEXX Laboratories Announces First Quarter Results

      Achieves first quarter revenue growth of 4% as reported and 5% organic, supported by CAG Diagnostics recurring revenue growth of 3% as reported and 4.5% organic. Organic revenue growth supported by benefits from IDEXX execution drivers, including continued solid new business gains and strong year-over-year global premium instrument installed base growth, including over 300 IDEXX inVue Dx™ placements. Delivers EPS of $2.96, an increase of 5% as reported and 7% on a comparable basis, supported by gross margin expansion of 90 basis points as reported and 80 basis points on a comparable basis. Adjusts 2025 revenue guidance to $4,095 million - $4,210 million, an increase of $40 million

      5/1/25 6:30:00 AM ET
      $IDXX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • IDEXX Laboratories to Release 2025 First Quarter Financial Results

      IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2025 first quarter financial results for Thursday, May 1, 2025, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q1 2025 Earnings Snapshot through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the webcast will be available after 1:00 p.m. ET on that day via the same link and will remain available for one year. The live call also will be accessible by telephone. To listen to t

      4/3/25 1:30:00 PM ET
      $IDXX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • IDEXX Laboratories Announces Fourth Quarter and Full Year 2024 Results

      Achieves fourth quarter revenue growth of 6% as reported and on an organic basis, driven by CAG Diagnostics recurring revenue growth of 6% reported and 7% organic Solid growth supported by continued benefits from IDEXX execution drivers, including 9% year-over-year expansion of IDEXX's global premium instrument installed base and net customer gains across testing modalities Delivers fourth quarter EPS of $2.62, an increase of 13% as reported and 10% on a comparable basis driven by strong operating results Provides initial outlook for 2025 revenue of $4,055 million - $4,170 million, reflecting growth of 4% - 7% reported and 6% - 9% organic, supported by CAG Diagnostics recurring

      2/3/25 6:30:00 AM ET
      $IDXX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $IDXX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Szostak M Anne exercised 1,046 shares at a strike of $160.28 and sold $1,182,917 worth of shares (2,306 units at $512.97) (SEC Form 4)

      4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)

      5/23/25 5:00:20 PM ET
      $IDXX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Director Junius Daniel M exercised 2,683 shares at a strike of $263.81 and sold $1,358,697 worth of shares (2,683 units at $506.41) (SEC Form 4)

      4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)

      5/14/25 5:00:15 PM ET
      $IDXX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Director Vandebroek Sophie V. exercised 1,279 shares at a strike of $283.59 and sold $628,425 worth of shares (1,279 units at $491.34) (SEC Form 4)

      4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)

      5/13/25 5:00:17 PM ET
      $IDXX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $IDXX
    Leadership Updates

    Live Leadership Updates

    See more
    • First Watch Announces Appointment of Irene Chang Britt to Board of Directors

      BRADENTON, Fla., July 19, 2023 (GLOBE NEWSWIRE) -- First Watch Restaurant Group, Inc. (NASDAQ:FWRG) ("First Watch" or the "Company"), the leading Daytime Dining concept serving breakfast, brunch and lunch, today announced the appointment of Irene Chang Britt to its Board of Directors, effective immediately. Ms. Chang Britt is an experienced independent board director and former Fortune 500 C-suite executive, who currently serves on the boards of established businesses and start-up companies representing a variety of industries, including retail, CPG, e-commerce and lifestyle. "We are thrilled to welcome Irene to the Board of Directors of First Watch, and I'm confident that our company wil

      7/19/23 4:15:00 PM ET
      $BHF
      $FWRG
      $IDXX
      $VSCO
      Life Insurance
      Finance
      Restaurants
      Consumer Discretionary
    • Ocular Therapeutix™ Appoints Merilee Raines to Its Board of Directors

      Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the appointment of Merilee Raines to the Company's Board of Directors effective September 20, 2021. "We are excited to welcome Merilee to our Board of Directors," said Antony Mattessich, President and Chief Executive Officer of Ocular Therapeutix. "Merilee brings a wealth of operational, financial, and business experience to our team. Having started as employee #11 at IDEXX, she helped to drive a multitude of innovative growth strategies and successfully scaled the business from sta

      9/22/21 8:00:00 AM ET
      $IDXX
      $OCUL
      $TMDX
      $WTS
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Biotechnology: Electromedical & Electrotherapeutic Apparatus